Four months after one of its scientists was snubbed for a Nobel Prize in medicine, a leading cancer center will ask a court to credit him in another way: by adding his name to patents underlying a major cancer immunotherapy drug made possible by the award-winning research.

Dana-Farber Cancer Institute on Monday will petition the U.S. District Court in Boston to include Gordon Freeman and a colleague on six patents issued by the U.S. Patent Office. Those patents currently name Nobel laureate Tasuku Honjo, two Kyoto University colleagues, and one scientist from the drug maker Ono Pharmaceutical.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy